Comparative Tolerability of Protease Inhibitors and the Associated Impact on Persistence, Healthcare Utilization, and Healthcare Costs.
Phase of Trial: Phase IV
Latest Information Update: 04 Dec 2012
At a glance
- Drugs Atazanavir; Darunavir; Fosamprenavir; Lopinavir
- Indications HIV infections
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 01 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Dec 2011 Planned end date changed from 1 Nov 2011 to 1 Oct 2012 as reported by ClinicalTrials.gov.
- 14 Oct 2011 New trial record